Search
Cupric sulfate
go.drugbank.com/drugs/DB06778ApprovedThe average daily intake of copper in the USA is approximately 1 mg Cu with the diet being a primary source [A32221]. … Copper is an essential trace element and an important catalyst for heme synthesis and iron absorption. After zinc and iron, copper is the third most abundant trace element found in the human body.
Mixtures: Se-Tan PLUS, Pnv-VP-UProducts: Micro CuImdevimab
go.drugbank.com/drugs/DB15940ApprovedInvestigationalCasirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA. … [A221495] On November 21, 2020, the FDA authorized emergency approval of REGN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older.
Cenegermin
go.drugbank.com/drugs/DB13926ApprovedInvestigationalCenegermin received approval from the US FDA a year later in August of 2018. [L4563] Neurotrophic keratitis is a degenerative disease resulting from a loss of corneal sensation. … [L4563] While the prevalence of neurotrophic keratitis is low, the impact of this serious condition and its associated sequelae on an individual patient can be debilitating.
Apixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalApixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic … Apixaban was approved by the FDA on December 28, 2012[L6043].
Products: Nra-apixaban, Nra-apixaban TabletsTagraxofusp
go.drugbank.com/drugs/DB14731ApprovedInvestigational[A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is … It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.
Palbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigationalIt is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. … [L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male
Synonyms: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-oneCilostazol
go.drugbank.com/drugs/DB01166ApprovedInvestigationalIt is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
mRNA-1345
go.drugbank.com/drugs/DB18739ApprovedInvestigationalmRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older.
Macimorelin
go.drugbank.com/drugs/DB13074ApprovedMacimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. … More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels
Paroxetine
go.drugbank.com/drugs/DB00715ApprovedInvestigational[T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.
Products: Nu-paroxetine, Nra-paroxetine